Startseite

Aktien

Maze Therapeutics

Nachrichten

Maze Therapeutics Aktie

Aktie

ISIN: US5787841007 WKN: A41188 SYM: MAZE Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

32,56

USD

+0,93 %

+0,30 USD

Letzter Kurs 02:00:00 Nasdaq

Maze Therapeutics Aktie kaufen

Geldkurs

12.11.25

32,56

USD

200 STK

Briefkurs

12.11.25

32,65

USD

100 STK

Verkauf

Kauf

Hinweis
Verlängerte Handelszeiten
Ab sofort von 07:30 bis 23:00 Uhr

Neueste Nachrichten

Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights 06.11.25 · globenewswire · Maze Therapeutics
Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week 06.11.25 · globenewswire · Maze Therapeutics
Maze Therapeutics to Participate in Four Upcoming Investor Conferences 04.11.25 · globenewswire · Maze Therapeutics
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors 06.10.25 · globenewswire · Maze Therapeutics
Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement 11.09.25 · globenewswire · Maze Therapeutics
Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) 11.09.25 · globenewswire · Maze Therapeutics
Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer 02.09.25 · globenewswire · Maze Therapeutics
Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights 12.08.25 · globenewswire · Maze Therapeutics
Maze Therapeutics to Participate in Two Upcoming Investor Conferences 10.07.25 · globenewswire · Maze Therapeutics
Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference 29.05.25 · globenewswire · Maze Therapeutics
Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones 14.05.25 · globenewswire · Maze Therapeutics
Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference 13.05.25 · globenewswire · Maze Therapeutics

1
2

Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 ... 104 Leser
Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights 24 Leser

Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 ... 104 Leser
Maze Therapeutics to Participate in Four Upcoming Investor Conferences 80 Leser
Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights 24 Leser

Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement 156 Leser
Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, ... 124 Leser
Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer 120 Leser
Maze Therapeutics to Participate in Two Upcoming Investor Conferences 120 Leser
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors 116 Leser
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights 112 Leser
Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference 108 Leser
Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 ... 104 Leser
Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights 104 Leser
Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones 104 Leser